Bitterly cold arctic air has blanketed parts of the United States over the last week, with some areas getting snow and subzero temperatures. Along with the cold weather comes a natural event called ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

John Seiler was strolling across Virginia Tech’s campus with his students Thursday morning when something stopped them in their tracks: a sweet cherry tree with an unusual jagged scar running along ...

Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. The majority of the United States is bracing itself for a ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...

Abstract: Single Image Super Resolution (SISR) is a post-processing technology for Internet of Things (IoT) devices that reduces bandwidth usage and improves communication efficiency. While most SISR ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...